William Blair analyst Andrew Brackmann has maintained their neutral stance on HOLX stock, giving a Hold rating on November 5.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Andrew Brackmann’s rating is based on a combination of factors, including Hologic’s recent fiscal fourth-quarter results and future growth projections. The company reported revenue that exceeded expectations, with a notable performance in the Breast Health segment, which returned to growth. However, despite these positive results, there are several risks that could impact future performance.
Key concerns include the potential delay or failure of the pending take-private transaction, as well as the possibility of slower-than-expected growth in the Breast Health segment. Additionally, challenges such as sustaining growth in molecular diagnostics, achieving earnings growth that outpaces revenue, successfully integrating new acquisitions, and potential reductions in hospital capital expenditures contribute to the Hold rating. These factors suggest a cautious approach, balancing the company’s current performance with uncertainties in its future outlook.
In another report released on November 5, UBS also maintained a Hold rating on the stock with a $76.00 price target.